Pinealon

Add links
Source: Wikipedia, the free encyclopedia.
(Redirected from Glu-Asp-Arg)
Pinealon
Clinical data
Other namesGlu-Asp-Arg
Identifiers
  • (4S)-4-Amino-5-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
CAS Number
PubChem CID
ChemSpider
ChEBI
Chemical and physical data
FormulaC15H26N6O8
Molar mass418.407 g·mol−1
3D model (JSmol)
  • C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N
  • InChI=1S/C15H26N6O8/c16-7(3-4-10(22)23)12(26)21-9(6-11(24)25)13(27)20-8(14(28)29)2-1-5-19-15(17)18/h7-9H,1-6,16H2,(H,20,27)(H,21,26)(H,22,23)(H,24,25)(H,28,29)(H4,17,18,19)/t7-,8-,9-/m0/s1
  • Key:QPRZKNOOOBWXSU-CIUDSAMLSA-N

Pinealon is a synthetic tripeptide of sequence (Glu-Asp-Arg) and purported geroprotector documented in the Russian scientific literature.[1][2][3][4]

Research

Pinealon has been shown to protect rat offspring from prenatal hyperhomocysteinemia and correspondingly improve post natal cognitive function.[5]

Pinealon likewise maintains learning retention rats with experimentally-induced diabetes.[6] As well as old humans and young wrestlers.[7]

Pinealon has been tested in large scale Human trials such as the Gasprom study, where it showed profound Geroprotective effects. This included longer telomeres and improvements in various health markers.[7]

Chemistry

Pinealon is a tripeptide composed of L-glutamic acid, L-aspartic acid, and L-arginine and is notated as Glu-Asp-Arg or EDR.[8]

References

  1. ^ Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva I (2015). "Effect of Synthetic Peptides on Aging of Patients with Chronic Polymorbidity and Organic Brain Syndrome of the Central Nervous System in Remission". Advances in Gerontology = Uspekhi Gerontologii. 28 (1): 62–67. PMID 26390612.
  2. ^ Mendzheritskiĭ AM, Karantysh GV, Ivonina KO (2011). "[Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats]". Advances in Gerontology = Uspekhi Gerontologii. 24 (1): 74–79. PMID 21809624.
  3. ^ Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A (October 2011). "Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes". Rejuvenation Research. 14 (5): 535–541. doi:10.1089/rej.2011.1172. PMID 21978084.
  4. ^ Kozina LS (2008). "[Investigation of antihypoxic properties of short peptides]". Advances in Gerontology = Uspekhi Gerontologii. 21 (1): 61–67. PMID 18546825.
  5. ^ Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V (2012-04-06). "Pinealon protects the rat offspring from prenatal hyperhomocysteinemia". International Journal of Clinical and Experimental Medicine. 5 (2): 179–185. PMC 3342713. PMID 22567179.
  6. ^ Karantysh GV, Fomenko MP, Menzheritskii AM, Prokof'ev VN, Ryzhak GA, Butenko EV (July 2020). "Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes". Neurochemical Journal. 14 (3): 314–320. doi:10.1134/S181971242003006X. ISSN 1819-7132. S2CID 255382498.
  7. ^ a b Yumpu.com. "GARMONIA Ltd. – visit u". yumpu.com. Retrieved 2024-06-11.
  8. ^ "Pinealon". PubChem. U.S. National Library of Medicine. Retrieved 2023-09-18.


Stub icon

This article about medicinal chemistry is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pinealon&oldid=1254192040"